23.08.2011 Copyright® Raisio Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and.

Slides:



Advertisements
Similar presentations
YOUR CHOLESTEROL WHY DO YOU CARE? WHAT YOU CAN DO !
Advertisements

Plant Sterols – a product case study
Plasma Lipids at diagnosis of Type 2 Diabetes UKPDS study group, Diabetes Care 1997; 20: (55)1.1 (43) 1.0 (39)HDL-C mmol/l (mg/dl) 1.8 (159)
Residual risk: Is LDL target enough?
Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.
Copyright® Raisio A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: Results.
Cholesterol Lipid Component of cell membrane Found in the diet – Eggs, dairy, liver High levels lead to development of CHD 2 types of cholesterol -carrying.
Weng TC, et al. J Clin Pharm Ther 2010;35:
The Science of Plant Stanol Ester. Contents Background Plant stanol ester and LDL-cholesterol lowering Dose-response of plant stanol ester with high daily.
Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.
Copyright® Raisio Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic.
Modern Management of Cholesterol in the High-Risk Patient.
Copyright® Raisio The effect of a very high daily plant stanol ester intake on serum lipids, carotenoids, and fat-soluble vitamins Gylling et.
Copyright® Raisio A plant stanol yogurt drink alone or combined with a low-dose statin lowers serum triacylglycerol and non-HDL cholesterol.
Copyright® Raisio Effects of long-term plant sterol or stanol ester consumption on lipid and lipoprotein metabolism in subjects on statin treatment.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Copyright® Raisio Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population Miettinen TA et.
Copyright® Raisio Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced.
Hyperlipidaemiák Szollár Lajos Klinikai kórélettan Szeptember 28.
Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.
Copyright® Raisio Effects on serum lipids, lipoproteins and fat soluble antioxidant concentrations of consumption frequency of margarines and.
Cholesterol-lowering effects of a stanol- ester containing low-fat margarine used in conjunction with a strict lipid-lowering diet Andersson A et al. Eur.
Plant stanol esters in human studies Professor Helena Gylling University of Kuopio.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
1 A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia Diabetes Care 28:1547–1554,
Date of download: 7/5/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of High vs Low Glycemic Index of Dietary Carbohydrate.
Parameters BD PP CP TC (mg. dl-l) ± * ± 5.8
Copyright © 2015 by the American Osteopathic Association.
Cholesterol-Lowering Ability of a Phytostanol Softgel Supplement in Adults with Mild to Moderate Hypercholesterolemia Woodgate D et al. Lipids. 2006;41:
Dyslipidemia and Diabetic Macular Edema
Plant stanol esters in low-fat yogurt reduces total and low-density lipoprotein cholesterol and low-density lipoprotein oxidation in normocholesterolemic.
Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.
ILLUMINATE - Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events.
First time a CETP inhibitor shows reduction of serious CV events
Copyright © 2012 American Medical Association. All rights reserved.
National Cholesterol Education Program
Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN 
Oxford Niacin Trial.
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN 
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Effect of evolocumab on lipoprotein particles
A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia  Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.
How to Teach it?.
Joshua A. Bell et al. JACC 2018;72:
Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN 
Description of studies for pooled analyses
Advances in Hypertriglyceridemia Treatment
I. Introduction American Journal of Kidney Diseases
Level of risk factor control in the overall sample and by gender
The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis  Moritz C. Wyler von Ballmoos, MD, MPH, Bernhard.
Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.
Body mass, BMI, plasma lipids, lipoproteins, and glucose homeostasis at baseline, and following placebo and rosuvastatin periods Dmitri Sviridov et al.
Goals & Guidelines A summary of international guidelines for CHD
Baseline Characteristics of the Subjects*
Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.
Disposition of Patients in the Atherogenic Dyslipidemia Study
(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.
Receiver operating curves (ROC) of simple age and gender adjusted risk factor models for predicting 10-year risk of cardiovascular disease comparing the.
Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.
Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),
Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.
Change in markers of glycometabolism and cardiovascular risk profile.
Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)
Individual lipid measures for high-carbohydrate (n=10) and low-carbohydrate (n=10) ultra-endurance athletes. Individual lipid measures for high-carbohydrate.
FIGURE 1 Results for primary meta-analysis of controlled trials for the effects of walnut-enriched compared with ... FIGURE 1 Results for primary meta-analysis.
LDL-c reductions below 1
The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.
Medication intensity (ALLP) changes between baseline and 6 months, by (not) being low-density lipoprotein-cholesterol (LDL-C) target at baseline for nurse-coordinated.
Presentation transcript:

Copyright® Raisio Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors Athyros et al. Nutr Metab Cardiovasc Dis 2011; 21(3):

Athyros et al. Nutr Metab Cardiovasc Dis Methods I Parallel, randomized, placebo-controlled study N=150, mildly hypercholesterolaemic (5,2–6,4 mmol/l) subjects 4-week run-in with a NCEP Step I diet, intervention for 16 weeks Placebo spread; NCEP Step I diet Plant stanol ester containing spread (2 g plant stanols/d); NCEP Step I diet Mediterranean diet

Athyros et al. Nutr Metab Cardiovasc Dis Methods II Outcome measures: Individual risk factors: changes in lipids and lipoproteins (TC, LDL-C, HDL-C, TG, apo B, apo A1) blood pressure haemostatic factors (plasma fibrinogen & PAI-1 activity) inflammatory marker (hsCRP) Estimated CVD risk (Framingham, PROCAM & Raynolds risk engines) Percentage of patients at NCEP Total Cholesterol target (< 5.2 mmol/l)

Athyros et al. Nutr Metab Cardiovasc Dis Results I Effect of intervention on risk factors: Placebo: no significant effect on any of the risk factors Plant stanol ester: TC, LDL and hsCRP (statistically significant change in all) Mediterranean diet: TC, LDL, TG, blood pressure, hsCRP and thrombotic markers ; HDL (statistically significant change in all)

Athyros et al. Nutr Metab Cardiovasc Dis * * ** * Plant Stanol Ester effectively lowers LDL-cholesterol Control spread n=50 Mediterranean diet n=50 Plant stanol ester spread (plant stanol 2 g/d) n=50 % CHANGE IN LDL-CHOLESTEROL * * % months * * * * p <0.01 vs. control

Athyros et al. Nutr Metab Cardiovasc Dis Results II Estimated cardiovascular disease risk: Placebo: no effect on estimated disease risk Plant stanol ester: eCVD risk reduction of 26–30 % in 1 month with all risk engines used, sustained the 4 months intervention Mediterranean diet: eCVD risk reduction of 24–32% in 4 months with all risk engines used

Athyros et al. Nutr Metab Cardiovasc Dis Effective reduction in the estimated risk of cardiovascular diseases with use of Plant Stanol Ester EFFECTIVE REDUCTION IN THE ESTIMATED RISK OF CORONARY ARTERY DISEASE (CAD) Control spread n=50 A change in the estimated CAD risk during the following 10 years (Framingham risk engine) Mediterranean diet n=50 Plant stanol ester spread (2 g of plant stanols / day) n=50 Months * * * * * *=p<0.05 vs. control

Athyros et al. Nutr Metab Cardiovasc Dis Results III Percentage of subjects meeting target level for total cholesterol (<5.2 mmol/L) by the end of the study: Placebo: 14 % Plant stanol ester: 80 % Mediterranean diet: 46 %

Athyros et al. Nutr Metab Cardiovasc Dis Conclusions Mediterranean diet was efficient in reducing the estimated CVD risk by several mechanisms but the change was fully seen only after 4 months Plant stanol ester reduced the estimated risk of CVD as effectively already after 1 month The use of plant stanol ester products is especially beneficial for those individuals who are unable to adopt Mediterranean diet

10 Thank You!